Defendant

Bristol Myers Squibb

1 case as defendant.

Cases
1
Active
0
1 closed
Filed
—
Top venue
S.D. New York
1 case

In re Pomalyst (pomalidomide) Antitrust Litigation

dismissed; leave to amend sought

Putative class actions filed beginning September 2023 against Celgene, Bristol Myers Squibb, and individuals alleging antitrust, consumer-protection, and unjust-enrichment claims relating to the Pomalyst patents, including the '647 family. In March 2025 the court dismissed the complaints, and plaintiffs sought leave to amend.